J Clin Neurol.  2018 Jan;14(1):98-99. 10.3988/jcn.2018.14.1.98.

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis

• Garnero M
• Fabbri S
• Gemelli C
• Benedetti
• Mancardi G
• Schenone A
• Grandis M

• KMID: 2399605
• DOI: http://doi.org/10.3988/jcn.2018.14.1.98

Abstract

No abstract available.

MeSH Terms

Immunoglobulins*
Myasthenia Gravis*
Immunoglobulins

Reference

1. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med. 1980; 93:55–56.

2. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004; 112:1–7.

3. Yoon MS, Gold R, Kerasnoudis A. Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord. 2015; 8:153–159.

4. Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study. PLoS One. 2016; 11:e0159993.